NEW YORK ( TheStreet) -- CHANGE IN RATINGS
ADTRAN (ADTN) downgraded at Think to Hold from Buy, ThinkEquity said. $35 price target. Fairly valued at current levels.
American Tower (AMT) rated new Outperform at Credit Suisse. $75 price target. Market is not pricing in long-term growth potential.
TD Ameritrade (AMTD) downgraded at Deutsche from Buy to Hold, Deutsche Bank said. Valuation call, based on a $20 price target.Armstrong World (AWI) downgraded at Keybanc from Buy to Hold, Keybanc said. Valuation call, as the stock is already pricing in double-digit EBITDA growth over the next couple of years. Blackrock (BLK) downgraded at Deutsche from Buy to Hold, Deutsche Bank said. Valuation call, based on a $210 price target. Buffalo Wild Wings (BWLD) downgraded at Wedbush from Outperform to Neutral, Wedbush said. $90 price target. Wing costs remain high. Crown Castle (CCI) rated new Neutral at Credit Suisse. Valuation call, based on a $54 price target. Coach (COH) rated new Buy at Argus Research. $90 price target. Company can continue to expand in China. Dana Holding (DAN) rated new Buy at BofA Merrill. $21 price target. Diversification to help drive success. Digital Realty Trust (DLR) downgraded at Jefferies to Hold from Buy, Jefferies said. $73 price target. Lowered on valuation. Endo Pharmaceuticals (ENDP) rated new Buy at Cantor Fitzgerald. $50 price target. Business is resilient and the company generates solid cash flow. Morgan Stanley (MS) downgraded at Deutsche from Buy to Hold, Deutsche Bank said. $22 price target. Macro outlook remains mixed. Microsoft (MSFT) upgraded at Argus from Hold to Buy, Argus Research said. $39 price target. Windows 8 should help the company compete in the tablet market. Par Pharmaceutical (PRX) rated new Neutral at JP Morgan. $40 price target. Broadening pipeline and capabilities with recent acquisitions. Royal Bank of Scotland (RBS) upgraded at UBS to Buy from Neutral, UBS said. $10.19 price target. Better GDP outlook supports a classic recovery play. Red Hat (RHT - Get Report) downgraded at Morgan Stanley from Overweight to Equal-weight, Morgan Stanley said. Valuation call, as the stock has outperformed by 24% year-to-date.